The medical field is constantly changing and innovating. Keep up-to-date with the latest news about C-Pulse® and Sunshine Heart here.
November 7, 2011 Patients implanted with the C-Pulse Heart Assist System demonstrated statistically significant improvement based on New York Heart Association class reduction, Quality of Life and Left Ventricular
October 19, 2011 October 19, 2011: Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for moderate to severe heart failure, today announced that the C-Pulse Heart Assist System will be featured in two clinical presentations at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The TCT symposium, sponsored by the Cardiovascular Research Foundation, will take place November 7 through 11 in San Francisco, California.
June 9, 2011 Sunshine Heart, Inc., a global medical device company focused on innovative technologies for Class III/ambulatory Class IV (moderate to severe) heart failure, today announced it has completed an initial animal study of a next-generation transcutaneous C-Pulse® Heart Assist System. The study, conducted at Texas Heart Institute in Houston, demonstrated that a combined driver and C-Pulse cuff implanted around the heart’s aorta can be successfully powered from a wireless, external battery unit. This fully-implantable C-Pulse model would eliminate the need for wires to breach the skin, thereby improving patient comfort and reducing the risk of infection.
May 19, 2011 Many a company has stumbled chasing the elusive dream of making an artificial heart or a small pump to provide some assistance to those whose heart is failing. Australia's Ventracor, which envisaged a pump to replace the crucial million left ventricle or chamber of the diseased heart , collapsed during the global financial crisis. As investors preferred to fund later stage businesses rather than riskier start-ups. Now a second Australian company, Sunshine Heart, has re-emerged with plans to take its inherently less risky heart assist device into clinical trials.
May 13, 2011 Sydney - Friday - May 13: SUNSHINE HEART (ASX:SHC) may have appreciated all the attention because the company provided one of the more complete responses to an ASX query we have seen recently, this time over a price rise from 4.9c on Tuesday to as high as 6.3c yesterday. The company offered several factors, the main one being that this week the company had been conducting an education roadshow with the CEO and a cardiac specialist from the US for institutional investors and members of the medical profession